Daré Bioscience, Inc. (NASDAQ:DARE) Sees Significant Growth in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 39,200 shares, a growth of 19.9% from the August 15th total of 32,700 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily volume of 47,400 shares, the days-to-cover ratio is currently 0.8 days.

Hedge Funds Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC grew its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. 6.70% of the stock is currently owned by institutional investors.

Daré Bioscience Stock Performance

NASDAQ DARE remained flat at $3.28 on Tuesday. The company’s stock had a trading volume of 7,207 shares, compared to its average volume of 47,656. The stock has a market cap of $27.62 million, a price-to-earnings ratio of -0.85 and a beta of 1.39. The firm has a fifty day moving average price of $3.46 and a 200-day moving average price of $4.47. Daré Bioscience has a 52 week low of $3.05 and a 52 week high of $7.56.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $2.09. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.60 million. As a group, equities analysts expect that Daré Bioscience will post -0.27 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.